Evogene Ltd., a computational chemistry company, has announced a scientific collaboration with Unravel Biosciences, Inc., a clinical-stage therapeutics company. The partnership aims to accelerate the discovery and optimization of a first-in-class small-molecule therapy designed to restore myelin and reverse neurological damage in demyelinating diseases, such as multiple sclerosis. By combining Evogene's ChemPassAI engine and generative chemistry capabilities with Unravel Biosciences' patient RNA-derived Living Molecular Twins™ platform, the companies seek to meet the urgent need for remyelination therapies and advance new treatment options for patients with limited choices.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evogene Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: LN58219) on January 07, 2026, and is solely responsible for the information contained therein.